Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > PD-1 > EP-154

PD-1 : PD-L2 [Biotinylated] Inhibitor Screening ELISA Kit

For research use only.

Order Now

    Materials Provided
    IDComponentsSize
    EP154-C01High-bind Plate1 plate
    EP154-C02Human PD-115 μg
    EP154-C03Biotinylated Human PD-L220 μg
    EP154-C04Anti-PD1 Neutralizing Antibody20 μg
    EP154-C05Streptavidin-HRP5 μg
    EP154-C06Coating Buffer12 mL
    EP154-C0710xWashing Buffer 50 mL
    EP154-C08Blocking Buffer50 mL
    EP154-C09Substrate Solution12 mL
    EP154-C10Stop Solution7 mL
  • Product Overview
    PD-1 : PD-L2 [Biotinylated] Inhibitor Screening ELISA Kit is based on a competition-ELISA method, is used to screening for inhibitors of human PD-1 binding to human PD-L2. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human PD-1 binding to human PD-L2.
  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

    Typical Data Please refer to DS document for the assay protocol.
     PD-1 TYPICAL DATA

    INHIBITION OF PD-1: PD-L2 [Biotinylated] BINDING BY ANTI-PD-1 NEUTRALIZING ANTIBODY
    Serial dilutions of Anti-PD-1 Neutralizing antibody (Catalog # EP154-C04) (1:1 serial dilution, from 5 μg/mL to 0.0098μg/mL) was added into PD-1: Biotinylated PD-L2 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

    • Clinical and Translational Updates

    Comments (0)

    Promotion & Exhibitions



    Drug Development Status

    • Number of Launched Drugs:20 Details
    • Number of Drugs in Clinical Trials:167 Details
    • Latest Research Phase:Phase 3 Clinical

    Datasheet & Documentation

    Request for DMF
    DMF (Drug Master File)

    New Product Launch

    Questions & Comments

    This web search service is supported by Google Inc.

    totop
    Call us
    Call us
    North America:
    +1 800-810-0816 (Toll Free)
    Asia & Pacific:
    +86 400-682-2521
    Fax
    Fax
    +1 888-377-6111
    Address
    Address
    1 Innovation Way, Newark, DE 19711, USA

    Leave a message